Patients with resected ALK-positive non-small-cell lung cancer (NSCLC) requiring adjuvant therapy typically receive platinum-based chemotherapy, which is associated with limited clinical benefit and considerable toxicity. Now, data from the phase III ALINA trial demonstrate the efficacy of the ALK inhibitor alectinib in this setting.

A total of 257 patients with resected stage IB–IIIA ALK-positive NSCLC were randomly assigned (1:1) to receive alectinib (for up to 24 months) or platinum-based chemotherapy (4 cycles). Disease-free survival (DFS) in the stage II–III (90% of patients) and intention-to-treat (ITT) populations was the primary end point. Crossover was not mandated.

需要辅助治疗的已切除ALK阳性非小细胞肺癌 (NSCLC)患者通常接受铂类化疗，但临床获益有限且毒性相当大。现在，III 期 ALINA 试验的数据证明了 ALK 抑制剂 alectinib 在这种情况下的功效。

总共 257 名已切除的 IB-IIIA 期ALK阳性 NSCLC 患者被随机分配 (1:1) 接受艾来替尼（长达 24 个月）或铂类化疗（4 个周期）。 II-III 期（90% 的患者）和意向治疗 (ITT) 人群的无病生存 (DFS) 是主要终点。交叉不是强制性的。